Summary
Background: There are few moderately active single-agents for the treatment of recurrent or metastatic head & neck cancer. Thus, the identification of novel active agents is warranted. We performed the present phase II trial to evaluate activity and toxicity of vinorelbine (VNB) in previously treated patients with advanced head & neck cancer.Patients and methods: 16 patients entered the study, 15 of whom were évaluable. The main characteristics were: M/F=14/1; median age of 58 yrs (18–67); median PS (Karnofsky score) of 70 (60–100); primitive tumor sites were: oropharynx in 5; larynx in 4, hypopharynx in 3, rhynopharynx in 2, and oral cavity in 1 patient; initial clinical stage was IV in 9, III in 4 and II in 2 patients. Previous treatments were: cisplatinum with concurrent radiotherapy in 6 and cisplatinum + fluorouracil (for at least 2 cycles) in 9 patients. VNB was given at the dose of 20 mg/m2 i.v. infusion for 1 hr, weekly, for a minimum of 8 doses. Response and toxicity were evaluated after at least 8 doses of VNB.Results: Overall, 139 courses of VNB were given (median 9, range 8–19). Objective responses were: partial response in 1 patient (6%); stable disease, lasting at least 2 months, in 4 patients (27%) and progression in the other 10 patients (67%). Three patients had a one week delay in subsequent courses due to severe hematological toxicity.Toxicities observed were: leucopenia of grade IV (W.H.O.) in 2 patients and of grade I-II in 12 patients; granulocytopenia of grade III in 1 patient and of grade IV in 2 patients; grade I-II anemia in 4 patients; grade II phlebitis in 3 patients; grade II constipation in 2 patients, grade I-II peripheral neuropathy in 3 patients, grade I-II nausea and vomiting in 4 patients, and grade II stomatitis in 2 patients. Conclusions: VNB, in this series of heavily pre-treated patients with head & neck cancer, did not reveal an antitumor activity of interest.
Similar content being viewed by others
References
Schantz SP, Harrison LB, Hong WK: Cancer of the head and neck. De Vita VT Jr, Hellman S, Rosemberg SA (eds) Philadelphia, USA, J.B. Lippincott Company, 1993, ch 22, pp 574–630
Potier P: The synthesis of Navelbine, prototype of a new series of vinblastine derivatives. Semin Oncol 16:2–4, 1989 (suppl 4)
Cros S, Wright M, Morimoto C, Gares M, Francois G: Experimental antitumor activity of navelbine (5′-noran-hydrovinblastine, vinorelbine). Semin Oncol 16:15–20, 1989 (suppl 4)
Mathé G, Reizenstein P: Phase I pharmacologic study of a new vinca-alkaloid: Navelbine. Cancer Lett 27:285–293, 1985
Fumoleau P, Delgado FA, Delozier T, Monnier A, Delgado MAG, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Monteuquet P: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252, 1993
Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC: A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol (CCT) 14:115–119, 1991
Hoogenstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13:346–353, 1961
Gebbia V, Testa V, Valenza R, Zerillo G, Restivo S, Ingria F, Cannata G, Gebbia N: A pilot study of vinorelbine on a weekly schedule in recurrent and/or metas-tatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A:1358–1359, 1993
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer (review). N Engl J Med 328:184–194, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Testolin, A., Recher, G., Cristoferi, V. et al. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. Invest New Drugs 12, 231–234 (1994). https://doi.org/10.1007/BF00873964
Issue Date:
DOI: https://doi.org/10.1007/BF00873964